Ryan D. Cassaday, MD, University of Washington/Fred Hutch

Closing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.

Led by Dr Armin Ghobadi, the panel reviews data from a study regarding CD19 CAR T-cell therapy use in adults with B-Cell ALL.

Dr Cassaday discusses data supporting the use of combination blinatumomab and pembrolizumab in patients with R/R ALL.

Dr Jabbour and fellow panelists share their thoughts on the benefits of Inotuzumab ozogamicin, particularly in a pre-allogeneic HSCT setting.

Dr Schiller summarizes results from the ZUMA-3 trial and poses thoughtful questions to fellow panelists regarding clinical significance.

Best practices and special considerations for effective therapy selection and sequencing in the relapsed/refractory ALL setting.

The panelists review highly anticipated results from the E1910 trial assessing combination blinatumomab/consolidation chemotherapy in patients with Philadelphia chromosome-negative ALL.

Gary J. Schiller, MD and fellow panelists discuss clinical trial outcomes presented at the ASH 2022 annual meeting relevant to patients with Philadelphia chromosome-positive ALL.

Focusing on Philadelphia chromosome-positive ALL, panelists review standard-of-care treatment practices.

Four clinicians share best practices for assessing minimal residual disease (MRD) for ALL, touching on how these practices are evolving over time.

Ryan Cassaday, MD, notes differences between prognoses for patients with ALL based-on age, subtype, and disease progression status.

Armin Ghobadi, MD, and fellow panelists discuss new data concerning patients most at risk for developing ALL.

A panel of experts briefly reviews how both pediatric and adult patients with acute lymphoblastic leukemia (ALL) typically present and describes a standard patient workup.

Elias Jabbour, MD, leads a discussion on the similarities and differences between ALL subtypes and their respective incidence rates.